Literature DB >> 3553356

The human tumor clonogenic assay as a model system in cell biology.

A W Hamburger.   

Abstract

The human tumor stem cell (clonogenic) assay (HTCA) is a soft agar system designed for growing fresh human tumor specimens in vitro. The assay has been extensively used in studies both of individual patients' response to chemotherapy and for screening new agents. The technical limitations of this assay have been extensively discussed. The use of this test as a model system to study fundamentals of tumor cell growth has not been stressed. The potentials and limitations of this assay for the study of the regulation of tumor growth are presented.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3553356     DOI： 10.1002/stem.5530050202

Source DB:  PubMed          Journal:  Int J Cell Cloning        ISSN： 0737-1454


  10 in total

1.  Stimulation of growth of human malignant lymphoma and lymphoid leukemia cells in vitro.

Authors:  E S Strobel; K J Bross; R Mertelsmann; F Herrmann
Journal:  Ann Hematol       Date:  1992-02       Impact factor: 3.673

2.  Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas.

Authors:  Francesca Boscolo Sesillo; Alessandra Sacco
Journal:  J Vis Exp       Date:  2019-09-13       Impact factor: 1.355

3.  Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells.

Authors:  Boaz Kigel; Asya Varshavsky; Ofra Kessler; Gera Neufeld
Journal:  PLoS One       Date:  2008-09-26       Impact factor: 3.240

4.  Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration.

Authors:  Changhua Zhou; Qiu Zhong; Lyndsay V Rhodes; Ian Townley; Melyssa R Bratton; Qiang Zhang; Elizabeth C Martin; Steven Elliott; Bridgette M Collins-Burow; Matthew E Burow; Guangdi Wang
Journal:  Breast Cancer Res       Date:  2012-03-14       Impact factor: 6.466

5.  Anticancer activity of a Gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma.

Authors:  Jun Hui Sze; Prahlad V Raninga; Kyohei Nakamura; Mika Casey; Kum Kum Khanna; Susan J Berners-Price; Giovanna Di Trapani; Kathryn F Tonissen
Journal:  Redox Biol       Date:  2019-08-28       Impact factor: 11.799

Review 6.  Mutation or not, what directly establishes a neoplastic state, namely cellular immortality and autonomy, still remains unknown and should be prioritized in our research.

Authors:  Shengming Zhu; Jiangang Wang; Lucas Zellmer; Ningzhi Xu; Mei Liu; Yun Hu; Hong Ma; Fei Deng; Wenxiu Yang; Dezhong Joshua Liao
Journal:  J Cancer       Date:  2022-07-04       Impact factor: 4.478

Review 7.  Tumor Chemosensitivity Assays Are Helpful for Personalized Cytotoxic Treatments in Cancer Patients.

Authors:  Engin Ulukaya; Didem Karakas; Konstantinos Dimas
Journal:  Medicina (Kaunas)       Date:  2021-06-19       Impact factor: 2.430

8.  Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes.

Authors:  Erika M von Euw; María M Barrio; David Furman; Michele Bianchini; Estrella M Levy; Cassian Yee; Yongqing Li; Rosa Wainstok; José Mordoh
Journal:  J Transl Med       Date:  2007-04-20       Impact factor: 5.531

9.  A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression.

Authors:  Erika M von Euw; María M Barrio; David Furman; Estrella M Levy; Michele Bianchini; Isabelle Peguillet; Olivier Lantz; Alejandra Vellice; Abraham Kohan; Matías Chacón; Cassian Yee; Rosa Wainstok; José Mordoh
Journal:  J Transl Med       Date:  2008-01-25       Impact factor: 5.531

10.  High expression of QSOX1 reduces tumorogenesis, and is associated with a better outcome for breast cancer patients.

Authors:  Nicolas Pernodet; François Hermetet; Pascale Adami; Anne Vejux; Françoise Descotes; Christophe Borg; Marjorie Adams; Jean-René Pallandre; Gabriel Viennet; Frédéric Esnard; Michèle Jouvenot; Gilles Despouy
Journal:  Breast Cancer Res       Date:  2012-10-25       Impact factor: 6.466
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.